Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts rate Celldex Therapeutics “Moderate Buy”: Ten of 13 analysts recommend buying the stock, with one strong-buy, one hold and one sell rating. The average 12-month price target is $56.08, above the latest $41.70 share price.
• Recent analyst actions were mixed but generally positive, including Guggenheim raising its target to $100, UBS increasing its target to $45 and Barclays to $53, while Cantor Fitzgerald cut its target to $61.
• Celldex reported a quarterly loss of $0.94 per share, beating expectations for a $1.06 loss, though revenue of $0.02 million fell well short of the $0.73 million estimate. Analysts expect a full-year loss of $4.13 per share.

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $56.0833.

Several analysts recently issued reports on CLDX shares. Guggenheim upped their price target on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a "buy" rating in a report on Monday, July 20th. Cantor Fitzgerald decreased their price objective on shares of Celldex Therapeutics from $67.00 to $61.00 and set an "overweight" rating for the company in a report on Wednesday, July 22nd. Wall Street Zen raised shares of Celldex Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Sunday, July 12th. UBS Group upped their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, June 10th. Finally, Barclays increased their price target on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th.

Institutional Trading of Celldex Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Celldex Therapeutics in the 3rd quarter worth approximately $42,000. Russell Investments Group Ltd. boosted its holdings in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 501 shares during the period. Quantbot Technologies LP bought a new stake in shares of Celldex Therapeutics during the 3rd quarter valued at about $63,000. Kestra Advisory Services LLC acquired a new stake in Celldex Therapeutics during the fourth quarter worth about $98,000. Finally, Advisory Services Network LLC acquired a new stake in Celldex Therapeutics during the third quarter worth about $139,000.

Celldex Therapeutics Stock Down 0.2%

CLDX stock opened at $41.70 on Thursday. Celldex Therapeutics has a 52-week low of $20.37 and a 52-week high of $45.14. The stock's 50 day moving average is $37.34 and its two-hundred day moving average is $32.53. The company has a market capitalization of $3.27 billion, a PE ratio of -9.59 and a beta of 0.87.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.12. The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.73 million. As a group, sell-side analysts anticipate that Celldex Therapeutics will post -4.13 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source